At the time of writing, Lyra Therapeutics Inc [LYRA] stock is trading at $0.10, up 7.02%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The LYRA shares have gain 7.72% over the last week, with a monthly amount drifted -36.64%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Lyra Therapeutics Inc [NASDAQ: LYRA] stock has seen the most recent analyst activity on May 07, 2024, when Jefferies downgraded its rating to a Hold and also revised its price target to $0.50 from $10. Previously, H.C. Wainwright downgraded its rating to Neutral on May 07, 2024, and dropped its price target to $2. On May 07, 2024, downgrade downgraded it’s rating to Underperform. William Blair downgraded its rating to a Mkt Perform. H.C. Wainwright started tracking with a Buy rating for this stock on August 31, 2023, and assigned it a price target of $12. In a note dated May 24, 2022, Cantor Fitzgerald initiated an Overweight rating and provided a target price of $15 on this stock.
For the past year, the stock price of Lyra Therapeutics Inc fluctuated between $0.08 and $5.65. Currently, Wall Street analysts expect the stock to reach $0.5 within the next 12 months. Lyra Therapeutics Inc [NASDAQ: LYRA] shares were valued at $0.10 at the most recent close of the market. An investor can expect a potential return of 400.0% based on the average LYRA price forecast.
Analyzing the LYRA fundamentals
According to Lyra Therapeutics Inc [NASDAQ:LYRA], the company’s sales were 1.53M for trailing twelve months, which represents an 43.15% jump. Gross Profit Margin for this corporation currently stands at -7.74% with Operating Profit Margin at -62.81%, Pretax Profit Margin comes in at -60.88%, and Net Profit Margin reading is -60.91%. To continue investigating profitability, this company’s Return on Assets is posted at -1.41, Equity is -2.66 and Total Capital is -1.79. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 2.97.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.0926 points at the first support level, and at 0.0862 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.1043, and for the 2nd resistance point, it is at 0.1096.
Ratios To Look Out For
It is important to note that Lyra Therapeutics Inc [NASDAQ:LYRA] has a current ratio of 3.41. Also, the Quick Ratio is 3.41, while the Cash Ratio stands at 3.21. Considering the valuation of this stock, the price to sales ratio is 4.27, the price to book ratio is 0.56.
Transactions by insiders
Recent insider trading involved Palasis Maria, Officer, that happened on Apr 09 ’25 when 39567.0 shares were purchased.
